Latest news

Debiopharm Extends SunRock Biopharma Partnership for Antibody-Drug Conjugates Targeting HER3 in EGFR Mutated Cancers

Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-Treat Cancers

Debiopharm joins discussions with international health organisations to fight anti-microbial resistance at the 2023 World AMR Congress

Debiopharm Shares Oncology Program Updates at ASCO 2023 for Novel WEE1 Inhibitor, and First-In-Class CA IX Theranostic Approach

Debiopharm Launches Phase 1 Research in Small Cell Lung Cancer with WEE1 inhibitor Debio 0123 to Outsmart DDR

Debiopharm Launches Phase 1/2 Combination Trial Investigating Brain-Penetrant Selective WEE1 Inhibitor for Brain Cancer Patients

Debiopharm Announces Launch of the Phase 1/2 GaLuCi Study for its CA IX-Targeted Radiopharmaceutical Program

Big Impact, Small Package: Debiopharm Launches a Wazoku Open-Innovation Challenge for Small Antibody Drug Conjugate Technology